1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Naproxen (sodium; free acid) |
| brand | String | Aleve (OTC), Naprosyn (Rx), Anaprox (Rx), Naprelan (ER), EC-Naprosyn (enteric-coated), Vimovo (with esomeprazole) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID)]] • [[:Category:Analgesics|Analgesic]] • [[:Category:Antipyretics|Antipyretic]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"' |
| starting_dose | String | OTC: 220 mg PO every 8-12 hours, max 660 mg/24h. Rx: 250-500 mg PO BID. Acute gout: 750 mg loading then 250 mg every 8 hours |
| preparations | String | OTC tablets 220 mg; Rx tablets 250, 375, 500 mg; ER tablets 375, 500, 750 mg (Naprelan); oral suspension 125 mg/5 mL; enteric-coated tablets (EC-Naprosyn) |
| fda_max | String | 1500 mg/day (Rx); 660 mg/24h (OTC, without provider direction) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | 30-60 minutes |
| duration | String | 8-12 hours (the long-duration feature relative to ibuprofen) |
| halflife | String | 12-17 hours'"`UNIQ--ref-00000029-QINU`"' |
| bioavailability | String | ~95% (oral)'"`UNIQ--ref-0000002A-QINU`"' |
| pregnancy | String | Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-0000002B-QINU`"' |
| legal | String | [[USLegal:Over-the-counter|OTC]] in US at ≤220 mg/tablet and ≤660 mg/day; [[USLegal:Prescription only|Rx-only]] at higher strengths |
